In win for compounders, FDA will review its decision to put Eli Lilly's tirzepatide on shortage list
In accepting the FDA’s motion, U.S. District Judge Mark Pittman put on hold a lawsuit filed by the Outsourcing Facilities Association (OFA), which called the FDA’s decision to remove tirzepatide from the shortage list a “reckless and arbitrary decision—lacking any semblance of lawful process.”
HealthDay on MSN3d
FDA Says Compounding Pharmacies Can Keep Making Weight-Loss Med Tirzepatide, for NowOn October 7, a compounding trade group filed a lawsuit challenging the agency's action, saying there was still a shortage of ...
Health on MSN3d
What the End of a Tirzepatide Shortage Would Mean for Access to Compounded Weight Loss DrugsIn response to a lawsuit, the FDA has said that it will reevaluate its previous decision to remove tirzepatide from its ...
Discover why Sagimet Biosciences' Denifanstat is a top contender in treating MASH, with FDA designation and strong financials ...
Facing a lawsuit, the Food and Drug Administration has decided to reconsider its decision to take popular weight-loss and diabetes drugs off of the national shortage list, which will allow compounding ...
But when the FDA announced on Oct. 2 that the shortage of tirzepatide had ended, that meant compounding pharmacies had to stop making it. For now though, according to the recent court filing ...
A rapid-fire reversal from the Food and Drug Administration has injected even more uncertainty into what was already a wild ...
The weight-loss drugs are linked with reduced rates of excess drinking and opioid overdoses, suggesting they may tamp down ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback